Levodopa

Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.

Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.

Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.

Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").

Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").

Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").